Calcipotriol
- Generic Name
- Calcipotriol
- Brand Names
- Calcitrene, Dovobet, Dovonex, Enstilar, Sorilux, Taclonex, Wynzora
- Drug Type
- Small Molecule
- Chemical Formula
- C27H40O3
- CAS Number
- 112965-21-6
- Unique Ingredient Identifier
- 143NQ3779B
- Background
Calcipotriol (INN) or calcipotriene (USAN) is a sythetic derivative of calcitriol or Vitamin D.
- Indication
For the treatment of moderate plaque psoriasis in adults.
- Associated Conditions
- Plaque psoriasis of the scalp, Psoriasis Vulgaris (Plaque Psoriasis)
- Associated Therapies
- -
SHP-141C in Plaque Type Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2012-07-20
- Last Posted Date
- 2014-07-11
- Lead Sponsor
- TetraLogic Pharmaceuticals
- Target Recruit Count
- 14
- Registration Number
- NCT01646567
- Locations
- 🇦🇺
Nucleus Network Limited, Melbourne, Victoria, Australia
LEO 90100 in the Treatment of Psoriasis Vulgaris
- Conditions
- Interventions
- First Posted Date
- 2012-02-22
- Last Posted Date
- 2016-05-09
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 303
- Registration Number
- NCT01536938
- Locations
- 🇺🇸
Dermatology Research Associates, Los Angeles, California, United States
🇺🇸Altman Dermatology Associates, Arlington Heights, Illinois, United States
🇺🇸Derm Research Center of New York, Stony Brook, New York, United States
A 12-Day Randomized, Blinded, Vehicle and Active Comparator-Controlled Study to Determine the Efficacy and Safety of Six Concentrations of Topical E6201 Gel in Subjects With Psoriasis Vulgaris
- Conditions
- Interventions
- First Posted Date
- 2010-12-31
- Last Posted Date
- 2021-06-11
- Lead Sponsor
- Eisai Limited
- Target Recruit Count
- 30
- Registration Number
- NCT01268527
- Locations
- 🇩🇪
Bioskin GmbH, Berlin, Germany
LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs)
- Conditions
- Interventions
- First Posted Date
- 2010-08-26
- Last Posted Date
- 2017-02-02
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 1152
- Registration Number
- NCT01188928
- Locations
- 🇺🇸
Horizon Research Group, Inc, Mobile, Alabama, United States
🇺🇸Advanced Clinical Research Institute, Anaheim, California, United States
🇺🇸DBA Torrance Clinical Research, Lomita, California, United States
A Single-Center Exploratory Study to Assess the Activity of CRx-197-002 in Plaque Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2008-11-24
- Last Posted Date
- 2009-01-15
- Lead Sponsor
- Zalicus
- Target Recruit Count
- 20
- Registration Number
- NCT00796211
- Locations
- 🇩🇪
ProInnovera, Muenster, Germany
LCD Solution Versus Calcipotriol Cream in the Treatment of Moderate Plaque Psoriasis
- First Posted Date
- 2008-06-27
- Last Posted Date
- 2008-11-19
- Lead Sponsor
- NeoStrata Company, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT00705900
- Locations
- 🇺🇸
Mass General Hospital: Clinical Unit for Research Trials in Skin, Boston, Massachusetts, United States
Efficacy and Safety of Calcipotriol Plus Hydrocortisone Ointment in Psoriasis Vulgaris on the Face and Skin Folds
- Conditions
- Interventions
- First Posted Date
- 2008-06-05
- Last Posted Date
- 2021-08-26
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 1245
- Registration Number
- NCT00691002
- Locations
- 🇵🇱
Latvia - managed by CRO, Warszawa, Poland
🇷🇸Serbia - managed by CRO, New Belgrade, Serbia
🇵🇱Hungary - managed by CRO, Warszawa, Poland
The Role of Calcipotriol as Radioprotector of Skin
- Conditions
- First Posted Date
- 2007-03-08
- Last Posted Date
- 2007-03-08
- Lead Sponsor
- Rabin Medical Center
- Target Recruit Count
- 50
- Registration Number
- NCT00445250
- Locations
- 🇮🇱
Rabin Medical Center, Petach Tiqva, Israel
Chronic Plaque Psoriasis Study With Topical Formulation Of GW786034
- Conditions
- Interventions
- First Posted Date
- 2006-07-31
- Last Posted Date
- 2017-11-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 10
- Registration Number
- NCT00358384
- Locations
- 🇫🇷
GSK Investigational Site, Paris, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.